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Summary
The molecular mechanisms mediating the anti-proliferative
effects of the murine anti-HER2 monoclonal antibody (4D5)
were investigated in HER2-overexpressing human carcinoma
cell lines. Treatment with 4D5 resulted in a dramatic accumu-
lation of BT-474 breast carcinoma cells in Gl; concomitant
with reduced expression of proteins involved in sequestration
of the cyclin E/Cdk2 inhibitor protein p27, increased associa-
tion of p27 with Cdk2 complexes and Cdk2 inactivation. No
equivalent effects were observed in BT-474 cells treated with a
control, non-inhibitory HER2 monoclonal antibody (FRP5)
or in a HER2-overexpressing cell line insensitive to 4D5 treat-
ment (MKN7 gastric carcinoma cells), confirming the rela-
tionship between these molecular changes and 4D5-mediated
inhibition of proliferation. Increased p27 expression was also
observed in 4D5-treated BT-474 cells; however an antisense
approach demonstrated that this increase was not required for
Cdk2 inactivation or establishment of the Gl block. These
data suggest that 4D5 interferes with HER2 receptor signal-
ing, resulting in downregulation of proteins involved in p27
sequestration. This causes release of p27, allowing binding and
inhibition of cyclin E/Cdk2 complexes and inhibition of Gl/S
progression. This model was confirmed using a second 4D5-
sensitive, HER2-overexpressing breast tumor line (SKBR3),
and suggests that the dependency of a given tumor cell on
elevated HER2-receptor signaling for the maintenance of p27
sequestration proteins may determine the clinical response to
treatment with the humanized anti-HER2 monoclonal anti-
body Herceptin® (trastuzumab).
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In a mammalian somatic cell, cell cycle progression is
regulated by the sequential activation of a family of
protein kinases, known as the cyclin-dependent kinases
(Cdks). In association with specific regulatory cyclin
subunits, these kinases play a major role in determining
whether cells proceed through each cell cycle phase or
make the transition from one cell cycle phase into the
next. One Cdk which plays a major role in determining
whether cells enter S phase and duplicate their DNA is
cyclin E/Cdk2. Together with cyclin D-dependent Cdks,
cyclin E/Cdk2 is involved in phosphorylating and inacti-
vating the growth-suppressor protein retinoblastoma.
This results in derepression of transcription factors that
modulate the expression of genes required for S phase
entry and progression. Due to the major role this kinase
plays at the Gl/S transition, the activation state of
cyclin E/Cdk2 is stringently regulated not only by phos-
phorylation/dephosphorylation events, but also through
association with a small inhibitory protein (p27). In
order for cells to go through the Gl/S transition, p27 is
made unavailable for binding to cyclin E/Cdk2 through
complex formation with p27-sequestration proteins
such as the cyclin D-dependent Cdks. Additionally,
p27 is targeted for degradation via ubiquitin-mediated
proteolysis, an event requiring phosphorylation of p27
by cyclin E/Cdk2 itself.
The anti-proliferative effects of the murine anti-
HER2 monoclonal antibody (4D5) on HER2-overex-
pressing tumor cell lines have been reported previously
[1-3] and, in ovarian carcinoma cells, this has been
correlated with increased p27 levels [4]. However, the
exact effect of 4D5 on cell cycle modulators has not been
fully elucidated until now (see Lane et al. [5]). Researchers
at the Friedrich Miescher Institute have compared the
effects of 4D5 with that of a non-inhibitory control
antibody, FRP5, which also binds to the extracellular
domain of HER2. The BT-474 breast tumor cell line was
chosen for this study because it is known to be exqui-
sitely sensitive to 4D5 treatment [2, 3]. BT-474 cells were
exposed to either FRP5 or 4D5 for 48 hours, or remained
untreated. Subsequent analysis by flow cytometry dem-
onstrated that control and untreated cells displayed a
normal cell cycle profile, whereas 4D5 treatment re-
sulted in almost total accumulation in the Gl phase,
suggesting a block in Gl/S progression. Consistent with
this Gl block, retinoblastoma protein was shown to be
in its hypophosphorylated, growth inhibitory form, and
cell cycle markers of S phase as well as G2/M were
absent. Most strikingly, however, a large increase in p27
protein expression was observed, which correlated with
increased association of p27 with Cdk2 and with Cdk2
inactivation.
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From these data, it was initially assumed that 4D5
was affecting HER2 receptor signaling, resulting in an
increase in p27, which then inhibited Cdk2 kinase and,
hence, prevented the Gl/S transition. However, more
detailed kinetics showed that p27 started to accumulate
only after eight hours 4D5 treatment, whereas cyclin
•E/Cdk2 inactivation was evident after two hours. More-
over, by eight hours, Cdk2 activity was already reduced
to 50% of that found in control cells. Further inves-
tigation revealed that p27 started to move onto Cdk2
complexes after two hours, where it subsequently accu-
mulated. This movement of p27 was shown to correlate
with the loss of proteins involved in p27 sequestration,
and decreased association of p27 protein with cyclin
D/Cdk4 complexes. The relationship between these
molecular changes and inhibition of proliferation was
confirmed by repeating the analysis with a HER2-over-
expressing cell line unaffected by 4D5 treatment (MKN7
gastric carcinoma cells). As expected, in MKN7 cells
no recruitment of p27 onto Cdk2 complexes occurred
following 4D5 treatment. Additionally, no equivalent
effects on the expression of proteins involved in p27
sequestration were observed.
The next stage was to determine whether increased
p27 protein levels are involved in establishing the Gl
block in BT-474 cells, or whether the movement of p27
onto Cdk2 complexes is sufficient. In order to address
this question, increased p27 protein expression in re-
sponse to 4D5 treatment was prevented using a p27
antisense approach. As expected, after 24 and 36 hours
of 4D5 treatment, control cells exhibited an increase in
p27 protein expression. In contrast, no increase in p27
levels was seen in antisense-treated cells. Despite this,
antisense-treated cells were found to block in Gl after 36
hours to a similar extent as observed in control cells.
This indicated that increased p27 protein expression is
not required for establishing the 4D5-induced Gl block
in BT-474 cells. Moreover, further analysis did indeed
reveal that Cdk2 was inactivated in p27 antisense-
treated cells. This occurred a little more slowly than in
control cells, but by 36 hours Cdk2 was almost totally
inactivated, as in the controls. This correlated with a
shift of p27 protein onto Cdk2 complexes in both con-
trol and antisense-treated cells.
Based on these data, a model of how 4D5 inhibits
proliferation in HER2-overexpressing cell lines was pro-
posed as follows. Treatment with 4D5 interferes with
HER2 receptor signaling, causing downregulation of
proteins involved in p27 sequestration. This results in
the release of p27, allowing it to bind and inhibit cyclin
E/Cdk2 complexes. Without this activity the cell cannot
go through the Gl/S transition, thereby delaying or even
halting cell cycle progression. An increase in p27 protein
expression also occurs in BT-474 cells. However, from
the antisense approach as well as p27 half-life studies,
this was postulated to be a consequence of cyclin E/
Cdk2 inactivation leading to inefficient targeting of p27
to the proteosome degradation machinery. This model
has been confirmed through analysis of a second 4D5-
sensitive, HER2-overexpressing breast tumor cell line
(SKBR3).
It was further speculated that the dependency of a
given tumor cell on elevated HER2 receptor signaling
for the maintenance of p27 sequestration proteins may
determine the clinical response to treatment with the
humanized anti-HER2 monoclonal antibody trastuzu-
mab (Herceptin). Future research, therefore, should focus
on elucidating what determines whether a cell becomes
dependent on HER2 overexpression during tumori-
genesis, and the relative contribution of other HER2
receptors to this phenomenon.
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